Acorda Therapeutics (ACOR) Jumps on Trials

Acorda Therapeutics Inc

gained 11.9% to $32.40 after the company reported that the Patent Trials and Appeal Board has denied both inter partes reviews of AMPYRA patents. Share volume totaled 2.2 million, or about quadruple its all-day average